Published online before print June 5, 2003, doi: 10.1161/01.ATV.0000080379.05071.22
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Association of High Coronary Heart Disease Risk Status With Circulating Oxidized LDL in the Well-Functioning Elderly
Findings From the Health, Aging, and Body Composition Study
From the Center for Experimental Surgery and Anesthesiology (P.H., P.V.), Katholieke Universiteit, Leuven, Belgium; the Intramural Research Program (T.B.H., E.M.S., L.H.C.), National Institute on Aging, National Institutes of Health, Bethesda, Md; the Department of Pathology (R.P.T.), University of Vermont, Burlington; the Division of Geriatric Medicine (A.B.N.), University of Pittsburgh, Pittsburgh, Pa; the Prevention Sciences Group (S.M.R.), University of California, San Francisco; and the Department of Preventative Medicine, University of Tennessee Health Science Center (S.B.K.), Memphis, Tenn.
Correspondence to Paul Holvoet, PhD, Center for Experimental Surgery and Anesthesiology (CEHA), University of Leuven, Campus Gasthuisberg, O&N, Herestraat 49, B-3000 Leuven, Belgium. E-mail paul.holvoet{at}med.kuleuven.ac.be
Objective— Although circulating oxidized LDL (oxLDL) is elevated in persons with coronary heart disease (CHD), whether oxLDL is elevated in persons with high CHD risk before any events is unknown. Therefore, we studied the association between high, predicted CHD risk and oxLDL in the Health ABC cohort.
Methods and Results— This cohort included 385 persons with CHD and 1183 persons at high risk; the latter were all persons with CHD risk equivalents: noncoronary forms of clinical atherosclerotic disease, diabetes, and a 10-year risk for CHD >20% by Framingham scoring. The remaining 1535 participants were at low risk. Levels of oxLDL were 1.18±0.61 mg/dL for low-risk persons, 1.50±0.81 mg/dL for high-risk persons without diagnosed CHD, and 1.32±0.83 mg/dL for persons with CHD (P<0.001). The odds ratio for high CHD risk in the highest quintile of oxLDL, compared with the lowest quintile and after adjusting for age, sex, race, LDL cholesterol, smoking status, and C-reactive protein, was 2.79 (P<0.001).
Conclusion— The odds ratio for elevated oxLDL among persons with high CHD risk before any CHD events was higher than that among persons with established CHD. A likely explanation is that once CHD is diagnosed, individuals are frequently treated with a statin, which is associated with lowering of LDL cholesterol and oxLDL levels.
Key Words: atherosclerosis • coronary heart disease • cardiovascular risk • lipoproteins • oxidized lipids
This article has been cited by other articles:
 |
|
 |
|
  E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Holvoet, D.-H. Lee, M. Steffes, M. Gross, and D. R. Jacobs Jr Association Between Circulating Oxidized Low-Density Lipoprotein and Incidence of the Metabolic Syndrome JAMA, May 21, 2008; 299(19): 2287 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ky, A. Burke, S. Tsimikas, M. L. Wolfe, M. G. Tadesse, P. O. Szapary, J. L. Witztum, G. A. FitzGerald, and D. J. Rader The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1653 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hamel, E. Abed, L. Brissette, and R. Moreau Characterization of oxidized low-density lipoprotein-induced hormesis-like effects in osteoblastic cells Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1021 - C1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dandapat, C. Hu, L. Sun, and J. L. Mehta Small Concentrations of oxLDL Induce Capillary Tube Formation From Endothelial Cells via LOX-1 Dependent Redox-Sensitive Pathway Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2435 - 2442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mor, D. Planer, G. Luboshits, A. Afek, S. Metzger, T. Chajek-Shaul, G. Keren, and J. George Role of Naturally Occurring CD4+CD25+ Regulatory T Cells in Experimental Atherosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 893 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mehta Oxidized or Native Low-Density Lipoprotein Cholesterol: Which Is More Important in Atherogenesis? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 980 - 982. [Full Text] [PDF]
|
|
|
|
|
|
T. Wu, W. C. Willett, N. Rifai, I. Shai, J. E. Manson, and E. B. Rimm Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, P. C. Davey, D. De Keyzer, M. Doukoure, E. Deridder, M.-L. Bochaton-Piallat, G. Gabbiani, E. Beaufort, K. Bishay, N. Andrieux, et al. Oxidized Low-Density Lipoprotein Correlates Positively With Toll-Like Receptor 2 and Interferon Regulatory Factor-1 and Inversely With Superoxide Dismutase-1 Expression: Studies in Hypercholesterolemic Swine and THP-1 Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1558 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. T. Willerson, and P. M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, T. B. Harris, R. P. Tracy, and S. B. Kritchevsky Oxidized LDL and the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): e31 - e31. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Holvoet, E. Macy, M. Landeloos, D. Jones, J. S. Nancy, F. Van de Werf, and R. P. Tracy Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Circulating Oxidized LDL Clin. Chem., April 1, 2006; 52(4): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ashfaq, J. L. Abramson, D. P. Jones, S. D. Rhodes, W. S. Weintraub, W. C. Hooper, V. Vaccarino, D. G. Harrison, and A. A. Quyyumi The Relationship Between Plasma Levels of Oxidized and Reduced Thiols and Early Atherosclerosis in Healthy Adults J. Am. Coll. Cardiol., March 7, 2006; 47(5): 1005 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cesari, S. B. Kritchevsky, B. J. Nicklas, B. W. H. J. Penninx, P. Holvoet, P. Koh-Banerjee, S. R. Cummings, T. B. Harris, A. B. Newman, and M. Pahor Lipoprotein Peroxidation and Mobility Limitation: Results From the Health, Aging, and Body Composition Study Arch Intern Med, October 10, 2005; 165(18): 2148 - 2154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koster, B. W. J. H. Penninx, H. Bosma, G. I. J. M. Kempen, T. B. Harris, A. B. Newman, R. N. Rooks, S. M. Rubin, E. M. Simonsick, J. T. M. van Eijk, et al. Is There a Biomedical Explanation for Socioeconomic Differences in Incident Mobility Limitation? J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2005; 60(8): 1022 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Durga, L. J. H. van Tits, E. G. Schouten, F. J. Kok, and P. Verhoef Effect of Lowering of Homocysteine Levels on Inflammatory Markers: A Randomized Controlled Trial Arch Intern Med, June 27, 2005; 165(12): 1388 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lapointe, J. Goulet, C. Couillard, B. Lamarche, and S. Lemieux A Nutritional Intervention Promoting the Mediterranean Food Pattern Is Associated with a Decrease in Circulating Oxidized LDL Particles in Healthy Women from the Quebec City Metropolitan Area J. Nutr., March 1, 2005; 135(3): 410 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Verreth, D. De Keyzer, M. Pelat, P. Verhamme, J. Ganame, J. K. Bielicki, A. Mertens, R. Quarck, N. Benhabiles, G. Marguerie, et al. Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-{alpha} and Peroxisome Proliferator-Activated Receptor-{gamma} Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice Circulation, November 16, 2004; 110(20): 3259 - 3269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Chang, S.-C. Lu, T.-C. Su, S.-F. Chou, W.-H. Huang, J. D. Morrisett, C.-H. Chen, C.-S. Liau, and Y.-T. Lee Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation J. Lipid Res., November 1, 2004; 45(11): 2116 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Holvoet, S. B. Kritchevsky, R. P. Tracy, A. Mertens, S. M. Rubin, J. Butler, B. Goodpaster, and T. B. Harris The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort Diabetes, April 1, 2004; 53(4): 1068 - 1073. [Abstract] [Full Text] [PDF]
|
|